ストックスクリーナーアプリを入手
13.38
2.92%
0.38
アフターアワーズ：
14.04
0.66
+4.93%
Maze Therapeutics Inc (MAZE) 最新ニュース
Cyclo Therapeutics reports promising NPC1 treatment findings - MSN
Maze Therapeutics begins Phase 2 trial for kidney disease drug By Investing.com - Investing.com Nigeria
Maze Therapeutics begins Phase 2 trial for kidney disease drug - Investing.com India
Maze Therapeutics Doses First Patient in Phase 2 HORIZON - GlobeNewswire
Maze Therapeutics Doses First Patient in Phase 2 HORIZON Clinical Trial Evaluating MZE829 as a Potential Treatment for APOL1 Kidney Disease - GlobeNewswire Inc.
Maze Therapeutics stock hugs flat line following $140M IPO - MSN
Maze Therapeutics valued at $690.4 million in lukewarm Nasdaq debut - MSN
Finance Watch: Metsera, Maze Go Public, Bringing 2025 US IPO Total To Three - News & Insights
Metsera and Maze Therapeutics Secure $415M in IPOs, Signaling Strong Start for US Health Care Industry - Hoodline
Maze Therapeutics IPO opens trading modestly higher - MSN
Maze Therapeutics valued at $690.4 million as shares rise marginally in market debut - MSN
Biotech firm Maze Therapeutics raises $140 million in US IPO - MSN
Maze Therapeutics IPO opens trading modestly higher By Investing.com - Investing.com Canada
4 Firms Guide Pair Of Biotech IPOs Raising $415M Combined - Law360
Maze Therapeutics Opens At $16.12, IPO Priced At $16 By Investing.com - Investing.com Canada
Metsera and Maze IPOs look to bring $415M to Nasdaq - BioWorld Online
FiDi-based obesity drug maker sees $1.9B IPO - Crain's New York Business
MAZE IPO NewsPrecision medicine biotech Maze Therapeutics prices upsized IPO at the $16 midpoint - Renaissance Capital
Two more biotechs, Metsera and Maze, cross IPO finish line - pharmaphorum
Maze Therapeutics Prices Upsized IPO at $16 Per Share -January 31, 2025 at 04:39 am EST - Marketscreener.com
Metsera and Maze Therapeutics Boost US Health Care IPOs to Record LevelsNews and Statistics - IndexBox, Inc.
Metsera, Maze secure combined $415 million in IPOs - BioPharma Dive
Drugmakers Metsera and Maze Raise Combined $415 Million in IPOs - Yahoo Finance
MAZEMaze Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Maze Therapeutics Prices Upsized IPO at $16, Raising $140M for Precision Medicine - StockTitan
Maze Therapeutics Announces Pricing of Upsized Initial Public Offering - GlobeNewswire
Maze Therapeutics Inc. (MAZE): Kidney Disease Biotech IPO Garnering Attention from Sector Investors - Smartkarma
Fenwick Represents Maze Therapeutics in $140 Million Upsized Initial Public Offering - Fenwick & West LLP
Three biotechs go public as IPO momentum increases - The Pharma Letter
Pompe Disease Pipeline 2024: Mechanism of Action, Route of Administration, and Clinical Trial Insights Explored by DelveInsight | M6P Therapeutics, Entrada Therapeutics, Maze Therapeutics, Astellas - The Globe and Mail
Obesity-Focused Metsera Leads Biotech Firms Eyeing IPOs - Law360
Drug developer Maze Therapeutics eyes up to $728 million valuation in US IPO - MSN
Maze Therapeutics Inc. (MAZE): Kidney Biotech with Blockbuster Potential Sets Terms for IPO - Smartkarma
Maze Therapeutics targets up to $728 million valuation in US IPO - MSN
Maze Therapeutics Files for 7.8M Share IPO at $15-$17/sh - Investing.com Canada
Maze Therapeutics Inc. (MAZE): Phase 2 Biopharma Targeting Kidney Disease Files for IPO. - Smartkarma
The Friday Biotech Perspective #36 - substack.com
Maze Therapeutics Seeks IPO For Trials Ramp-Up (Pending:MAZE) - Seeking Alpha
Metsera, Maze will play canary in the IPO coal mine - BioCentury
Kidney disease drugmaker Maze files for IPO - BioPharma Dive
Peninsula company angles to be Bay Area's first biotech IPO of 2025 - The Business Journals
Maze Therapeutics raises $115m to advance kidney disease candidates - Pharmaceutical Technology
Maze Therapeutics Announces Oversubscribed $115 Million Financing to Support Advancement of Clinical-Stage Programs and Future Pipeline - Business Wire
Maze Therapeutics Reports Positive First-in-Human Data From Phase 1 Healthy Volunteer Clinical Trial Evaluating MZE829 as a Potential Treatment for APOL1 Kidney Disease (AKD) - BioSpace
Maze Therapeutics to Present New Data Supporting Advancement of MZE829 and MZE782 Clinical Development at American Society of Nephrology’s Kidney Week and American Society of Human Genetics Annual Meeting - Business Wire
Maze Therapeutics Initiates Phase 1 First-in-Human Trial Evaluating MZE782 as a Potential Treatment for Chronic Kidney Disease - Business Wire
Navigating the IPR maze: India's pharmaceutical challenge - Express Pharma
Maze Therapeutics - The Pharma Letter
Regulators caused breakup of potential $750 million drug deal — now they've blessed company's latest move - The Business Journals
Maze Therapeutics discovers new SLC6A19 inhibitors - BioWorld Online
New SLC6A19 inhibitors divulged in Jnana Therapeutics patents - BioWorld Online
Maze Therapeutics presents new APOL1 inhibitors - BioWorld Online
Maze Therapeutics to Participate in Upcoming Investor Conferences - Business Wire
Antitrust M&A Snapshot | Q4 2023 - McDermott Will & Emery
Biopharma’s FTC headache deepens with guideline shifts years in the making - PharmaVoice
Nine biotech companies to watch in 2024 - Labiotech.eu
Sanofi Drops Acquisition of Maze’s Pompe Disease Drug After FTC Challenge - BioSpace
Sanofi terminates deal on drug license after US FTC objects - Reuters
Maze Therapeutics describes new APOL1 inhibitors - BioWorld Online
Chronic Kidney Disease Pipeline Booms as 90+ Therapies Likely to Enter in the Treatment Domain | DelveInsight - GlobeNewswire
Sanofi strikes a $150M deal for Maze’s Pompe disease drug - BioPharma Dive
Preclinical data presented for Maze Therapeutics’ APOL1 pore function inhibitor MZ-301 - BioWorld Online
Movers & Shakers: CEO Shakeups at BIO, Passage Bio and Palisade Bio - BioSpace
Maze Therapeutics patents new GYS1 inhibitors - BioWorld Online
Phenylketonuria (PKU) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update - GlobalData
Top Life Sciences Startups to Watch in 2020 - BioSpace
1.03%
大文字化:
|
ボリューム (24 時間):